Vol 2022, No 3 (2022)

March

Table of Contents

Research & Development

Bristol Myers Squibb Signs US$1.1 B Metastatic Cancer Pact with Volastra Abstract pdf html
Lucy Haggerty

Licensing

Endpoint Health and Grifols Collaborate to Develop Antithrombin III for Sepsis Abstract pdf html
Ayush Saxena & Lucy Haggerty
Novartis Delves Further into AAV Gene Therapies with US$1.65 B Voyager Deal Abstract pdf html
Lucy Haggerty
Sanofi Enters Multi-Billion Dollar Antibody Deals with Adagene and IGM Abstract pdf html
Lucy Haggerty

Mergers & Acquisitions

Biocon Biologics Acquires Viatris’ Biosimilar Portfolio for US$3.3 B Abstract pdf html
Lucy Haggerty

Opinion & Analysis

IQVIA Pharma Deals Review of 2021 Abstract pdf
Heather Cartwright, Taskin Ahmed & Lucy Haggerty


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.